Evidence map›Paper›PMID 37734866›Full record

ReviewCold Spring Harbor perspectives in medicine2024

Optogenetic Vision Restoration.

Volker Busskamp, Botond Roska, Jose-Alain Sahel

Abstract readReview
In one paragraph

Review in Cold Spring Harbor perspectives in medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Optogenetic vision restoration in the face of secondary and tertiary remodeling in the rd1 mouse retina.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Article
  6. Review
  7. Turning ON the inner retinal circuity: An exciting new approach to optogenetic therapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Article
  8. Review
  9. Sensing a rainbow of colors: algal photoreceptors.Frontiers in plant science · 2025
    Review
  10. Article
  11. Overview of Retinal Gene Therapy: Current Status and Future Challenges.Cold Spring Harbor perspectives in medicine · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Volker BusskampDegenerative Retinal Diseases, University Hospital Bonn, 53127 Bonn, Germany.
Botond RoskaInstitute of Molecular and Clinical Ophthalmology Basel, 4031 Basel, Switzerland.
Jose-Alain SahelDepartment of Ophthalmology, UPMC Vision Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA sahelja@upmc.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Optogenetics has emerged over the past 20 years as a powerful tool to investigate the various circuits underlying numerous functions, especially in neuroscience. The ability to control by light the activity of neurons has enabled the development of therapeutic strategies aimed at restoring some level of vision in blinding retinal conditions. Promising preclinical and initial clinical data support such expectations. Numerous challenges remain to be tackled (e.g., confirmation of safety, cell and circuit specificity, patterns, intensity and mode of stimulation, rehabilitation programs) on the path toward useful vision restoration.

Indexed as

OptogeneticsAnimalsHumans

Identifiers

PMID37734866
PMCPMC11293536

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.